TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16579728

Group type: EXPERIMENTAL
Intervention: Fresh grapefruit
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Grapefruit capsules
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Grapefruit (all forms)
Number of subjects: 91
Study: 12803788

Group type: EXPERIMENTAL
Intervention: Perioperative amoxycillin
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 10926979

Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2%
Number of subjects: 40

Group type: COMPARATOR
Intervention: Dorzolamide 2%
Number of subjects: 40
Study: 9208491

Group type: EXPERIMENTAL
Intervention: Hydroxyprogesterone caproate (HPC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tamoxifen (TMX)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aminoglutethimide (AG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined drugs (HPC + TMX, HPC + AG, TMX + AG)
Number of subjects: 0
Study: 1443204

Group type: EXPERIMENTAL
Intervention: Cycle ergometer exercise for 30 minutes
Number of subjects: 22

Group type: COMPARATOR
Intervention: Nonexercise control period
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Local heating to vasodilate forearm skin
Number of subjects: 22
Study: 7016089

Group type: EXPERIMENTAL
Intervention: Combined fluoride treatment (gel + rinse)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gel treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rinse treatment
Number of subjects: 0
Study: 30714486

Group type: EXPERIMENTAL
Intervention: Scrambler Therapy (ST)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Sham Treatment
Number of subjects: 35
Study: 31099712

Group type: EXPERIMENTAL
Intervention: Ertapenem
Number of subjects: 80

Group type: COMPARATOR
Intervention: Gentamicin plus Metronidazole
Number of subjects: 80
Study: 28724185

Group type: EXPERIMENTAL
Intervention: Myo-inositol plus selenium (MI-Se) supplementation
Number of subjects: 168

Group type: COMPARATOR
Intervention: Selenium alone
Number of subjects: 168
Study: 26270587

Group type: EXPERIMENTAL
Intervention: Anesthetic cream applied to the forearm
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo application
Number of subjects: 12
Study: 24103057

Group type: EXPERIMENTAL
Intervention: Screening group (50%)
Number of subjects: 12058

Group type: COMPARATOR
Intervention: Control group (50%)
Number of subjects: 12058

Group type: EXPERIMENTAL
Intervention: Screening protocol tests
Number of subjects: 12058

Group type: EXPERIMENTAL
Intervention: Screening protocol
Number of subjects: 12058

Group type: EXPERIMENTAL
Intervention: Overall study
Number of subjects: 12058
Study: 20672903

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided aspiration of hydrosalpingeal fluid prior to IVF-ET
Number of subjects: 110

Group type: COMPARATOR
Intervention: IVF-ET without any prior intervention
Number of subjects: 110
Study: 19169319

Group type: EXPERIMENTAL
Intervention: 2% chloroprocaine-bupivicaine
Number of subjects: 136

Group type: COMPARATOR
Intervention: 2% lidocaine-bupivicaine
Number of subjects: 136
Study: 16450373

Group type: EXPERIMENTAL
Intervention: Polyvalent, shed antigen, melanoma vaccine
Number of subjects: 117

Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 117
Study: 16873344

Group type: EXPERIMENTAL
Intervention: Sodium citrate 30 mL p.o. and saline 2 mL i.v.
Number of subjects: 123

Group type: COMPARATOR
Intervention: Water 30 mL p.o. and famotidine 20 mg i.v.
Number of subjects: 123
Study: 12517843

Group type: EXPERIMENTAL
Intervention: NucliSens HIV-1 QT assay
Number of subjects: 101

Group type: COMPARATOR
Intervention: Standard AMPLICOR test
Number of subjects: 101

Group type: COMPARATOR
Intervention: NASBA assay
Number of subjects: 101
Study: 10193813

Group type: EXPERIMENTAL
Intervention: L‐NMMA treatment (3 mg/kg) after pretreatment with CAND (8 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: L‐NMMA treatment (3 mg/kg) after placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: CAND pretreatment
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: L‐NMMA treatment (3 mg/kg)
Number of subjects: 15
Study: 8787253

Group type: EXPERIMENTAL
Intervention: Indomethacin 100 mg suppositories
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (Anusol)
Number of subjects: 30
Study: 2194387

Group type: EXPERIMENTAL
Intervention: Single general practitioner visit backed up by a practice nurse
Number of subjects: 100
Study: 7053160

Group type: EXPERIMENTAL
Intervention: Marihuana inhalation
Number of subjects: 18
Study: 29240962

Group type: EXPERIMENTAL
Intervention: AXXESS dedicated self‐expanding biolimus A9‐eluting bifurcation stent
Number of subjects: 123
Study: 28350654

Group type: EXPERIMENTAL
Intervention: Fibrin glue (Tisseel) (n = 23)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (n = 26)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Normal saline (control) (n = 27)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Donor-site quilting sutures (n = 20)
Number of subjects: 96
Study: 25246239

Group type: EXPERIMENTAL
Intervention: Vitamin C (500 mg), Vitamin E (400 mg), Zinc gluconate (25 mg), Selenomethionine (200 μg)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Vitamin C, Vitamin E, Zinc, and Selenium supplementation
Number of subjects: 53
Study: 24001635

Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention (six 90-minute sessions)
Number of subjects: 54
Study: 20963843

Group type: EXPERIMENTAL
Intervention: Biofilm testing for antibiotic selection
Number of subjects: 39

Group type: COMPARATOR
Intervention: Conventional antibiotic treatment
Number of subjects: 39
Study: 18534087

Group type: EXPERIMENTAL
Intervention: Minocycline 150 mg p.o. twice daily
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 16905684

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 284

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 284
Study: 12885990

Group type: EXPERIMENTAL
Intervention: Heterozygosity at position 27 of the β2 adrenergic receptor (ADRB2) polymorphism
Number of subjects: 587

Group type: EXPERIMENTAL
Intervention: Polymorphism at position 16 of the β2 adrenergic receptor (ADRB2)
Number of subjects: 587
Study: 11789186

Group type: EXPERIMENTAL
Intervention: Chang'ai Kangfu decoction (CAKF)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Combination therapy (CAKF plus chemotherapy)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Chemotherapy (5-FU and mitomycin C)
Number of subjects: 48
Study: 8888416

Group type: EXPERIMENTAL
Intervention: KR after every trial
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Summary KR
Number of subjects: 2
Study: 1892680

Group type: EXPERIMENTAL
Intervention: High-dose metoclopramide plus methylprednisolone (arm A)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: High-dose metoclopramide plus methylprednisolone plus lorazepam (arm B)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Both regimens (arm A and arm B)
Number of subjects: 163
Study: 6643694

Group type: EXPERIMENTAL
Intervention: 10 mg/kg dyphylline
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 15 mg/kg dyphylline
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 20 mg/kg dyphylline
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 6 mg/kg anhydrous theophylline
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31848050

Group type: EXPERIMENTAL
Intervention: Bivalent Oral Polio Vaccine (bOPV)
Number of subjects: 1038

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 1038
Study: 29557821

Group type: EXPERIMENTAL
Intervention: Patient-selected exercise adherence strategies (logs, graphs, pedometers, phone follow-up, education, and a letter from CR staff) provided for 6 weeks post CR and continued based on patient selection for the last 6 weeks.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 20
Study: 28112023

Group type: EXPERIMENTAL
Intervention: Phenylephrine (induced hypertension)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Polygeline (intravascular volume load)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Acetazolamide (cerebral arteriolar vasodilation)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Head down tilt (HDT) 15° (cerebral blood flow diversion)
Number of subjects: 118

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 118
Study: 27455513

Group type: EXPERIMENTAL
Intervention: Levomilnacipran extended-release (ER)
Number of subjects: 429

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 429
Study: 25530294

Group type: EXPERIMENTAL
Intervention: Active educational intervention (21 physicians) consisting of 1 small group discussion, 1 outreach visit, and 3 reminders.
Number of subjects: 317

Group type: COMPARATOR
Intervention: Passive educational intervention (20 physicians) consisting of delivery of printed guidelines.
Number of subjects: 317
Study: 22618381

Group type: EXPERIMENTAL
Intervention: Cathodal transcranial direct current stimulation (tDCS)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 12
Study: 19679019

Group type: EXPERIMENTAL
Intervention: Alcohol-based hand foam used to cleanse hands and stethoscope head simultaneously
Number of subjects: 92

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 92
Study: 17241248

Group type: EXPERIMENTAL
Intervention: Combined hepatitis A and B vaccine (Twinrix) administered at 0, 7, 21 to 30 days, and 12 months
Number of subjects: 100

Group type: COMPARATOR
Intervention: Monovalent hepatitis B vaccine (Engerix-B) administered at 0, 1, 2, and 12 months
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combined hepatitis A and B vaccine (Twinrix)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Monovalent hepatitis A vaccine (Havrix)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Monovalent hepatitis B vaccine (Engerix-B)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Monovalent vaccines (Havrix and Engerix-B)
Number of subjects: 100
Study: 15274701

Group type: EXPERIMENTAL
Intervention: Subcutaneous alprostadil (low doses) with saline solution intravenously
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intravenous alprostadil with local saline solution injections
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saline solution around the ulcers and intravenously (Control)
Number of subjects: 80
Study: 11526545

Group type: EXPERIMENTAL
Intervention: Entecavir 0.05 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Entecavir 0.1 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Entecavir 0.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Entecavir 1.0 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9248873

Group type: EXPERIMENTAL
Intervention: Moclobemide (150 mg twice a day, doubled after 3 weeks if needed)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg q.a.m., doubled after 3 weeks if needed)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Benzodiazepines (as comedication)
Number of subjects: 41
Study: 8499506

Group type: EXPERIMENTAL
Intervention: Insulated head cover applied within 1 minute of arrival in the operating room
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no insulated head cover)
Number of subjects: 0
Study: 3323227

Group type: EXPERIMENTAL
Intervention: Written interpretation of Gram stain results
Number of subjects: 301

Group type: COMPARATOR
Intervention: Control group (Gram stain results reported without interpretation)
Number of subjects: 301
Study: 31750703

Group type: EXPERIMENTAL
Intervention: 12-hr nicotine deprivation
Number of subjects: 120

Group type: COMPARATOR
Intervention: Nondeprived
Number of subjects: 120
Study: 30558092

Group type: EXPERIMENTAL
Intervention: Intrathecal hyperbaric ropivacaine (15.2 mg) with 5 μg sufentanil
Number of subjects: 100

Group type: COMPARATOR
Intervention: Prophylactic infusion of phenylephrine (50 μg/min)
Number of subjects: 100
Study: 27433861

Group type: EXPERIMENTAL
Intervention: Hypertrophic resistance training (RT) for 6 weeks, two 40-minute sessions weekly, three sets of 12 repetitions at 67% to 85% one-repetition maximum for 10 whole-body exercises.
Number of subjects: 37
Study: 25293375

Group type: EXPERIMENTAL
Intervention: EPDS cutoff point ≥8
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: EPDS cutoff point ≥8 (women)
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: EPDS cutoff point ≥7 (men)
Number of subjects: 447
Study: 22990352

Group type: EXPERIMENTAL
Intervention: Felodipine (5 mg/day)
Number of subjects: 9711

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9711

Group type: EXPERIMENTAL
Intervention: Add-on therapy (further diuretic and other drugs)
Number of subjects: 9711

Group type: COMPARATOR
Intervention: No-add-on therapy
Number of subjects: 9711
Study: 21109670

Group type: EXPERIMENTAL
Intervention: Values affirmation intervention (students wrote about their most important values, twice at the beginning of the course)
Number of subjects: 399

Group type: COMPARATOR
Intervention: Control group (students did not write about their values)
Number of subjects: 399
Study: 19075206

Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation
Number of subjects: 252

Group type: COMPARATOR
Intervention: Outpatient, hospital-based rehabilitation
Number of subjects: 252
Study: 16099421

Group type: EXPERIMENTAL
Intervention: Distraction
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Sensory-focussing
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (no imagery)
Number of subjects: 120
Study: 12548129

Group type: EXPERIMENTAL
Intervention: Oral ganciclovir (1 g every 8 hr) after IV ganciclovir (6 mg/kg per day for 14 days)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Oral acyclovir (800 mg every 6 hr) after IV ganciclovir (6 mg/kg per day for 14 days)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Oral ganciclovir
Number of subjects: 219

Group type: COMPARATOR
Intervention: Oral acyclovir
Number of subjects: 219
Study: 10077376

Group type: EXPERIMENTAL
Intervention: Esmolol group (ES, n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Blood cardioplegia group (BC, n = 30)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Esmolol group (ES)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Blood cardioplegia group (BC)
Number of subjects: 60
Study: 7720762

Group type: EXPERIMENTAL
Intervention: 2 mg nicotine gum
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 2242108

Group type: EXPERIMENTAL
Intervention: Formula with casein-to-whey ratio of 82:18
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High-casein formula (82:18)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Formula-fed groups (decreasing casein concentration)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Human milk
Number of subjects: 40
Study: 7261627

Group type: EXPERIMENTAL
Intervention: Estrogen treatment group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dextrothyroxine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30817251

Group type: EXPERIMENTAL
Intervention: PROSTVAC (Arm V)
Number of subjects: 1297

Group type: EXPERIMENTAL
Intervention: PROSTVAC plus granulocyte-macrophage colony-stimulating factor (Arm VG)
Number of subjects: 1297

Group type: COMPARATOR
Intervention: Placebo (Arm P)
Number of subjects: 1297

Group type: EXPERIMENTAL
Intervention: Adverse events (all groups)
Number of subjects: 1297
Study: 29976247

Group type: EXPERIMENTAL
Intervention: WASH and nutrition interventions delivered by Community Health Workers (CHWs)
Number of subjects: 4169

Group type: EXPERIMENTAL
Intervention: Monitoring of CHW performance
Number of subjects: 4169
Study: 27253216

Group type: EXPERIMENTAL
Intervention: Active tDCS (2 mA for 30 min)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Sertraline 50 mg/d
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo sertraline
Number of subjects: 120
Study: 24282136

Group type: EXPERIMENTAL
Intervention: 5-degree reverse Trendelenburg position (5-RTP)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 10-degree reverse Trendelenburg position (10-RTP)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 20-degree reverse Trendelenburg position (20-RTP)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Comparison of 5-RTP vs 20-RTP
Number of subjects: 75
Study: 23171354

Group type: EXPERIMENTAL
Intervention: Intervention group (n=171 workers)
Number of subjects: 293

Group type: COMPARATOR
Intervention: Control group (n=122 workers)
Number of subjects: 293
Study: 20515580

Group type: EXPERIMENTAL
Intervention: Forskolin (10 mg capsule orally per day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Beclomethasone (two 50 microg inhalations every 12 h)
Number of subjects: 60
Study: 18831357

Group type: EXPERIMENTAL
Intervention: Ramipril (2.5 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Losartan (50 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 15677776

Group type: EXPERIMENTAL
Intervention: BIAsp 70/30
Number of subjects: 233

Group type: COMPARATOR
Intervention: Glargine
Number of subjects: 233
Study: 12073665

Group type: EXPERIMENTAL
Intervention: RBC 400 mg bd and clarithromycin 500 mg bd for 14 days
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: RBC 400 mg bd, clarithromycin 500 mg bd and amoxycillin 1 g bd for 7 days
Number of subjects: 137
Study: 10091625

Group type: EXPERIMENTAL
Intervention: Write continuously for 30 min after btx A injection
Number of subjects: 8

Group type: COMPARATOR
Intervention: Rest for 30 min after btx A injection
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Btx A treatment
Number of subjects: 8
Study: 7789082

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG) 564.5 mg/day as add-on therapy (plus CBZ)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 2128415

Group type: EXPERIMENTAL
Intervention: Fenfluramine (60 mg PO 90 min before TRH)
Number of subjects: 22

Group type: COMPARATOR
Intervention: TRH (200 micrograms IV bolus)
Number of subjects: 22
Study: 371348

Group type: EXPERIMENTAL
Intervention: High dose dexamethasone therapy (1 mg/kg) within six hours of injury, repeated at six hours, maintained at 1 mg/kg/day for eight days.
Number of subjects: 9

Group type: COMPARATOR
Intervention: None or low dose regimen (0.25 mg/kg/day).
Number of subjects: 9
Study: 7093613

Group type: EXPERIMENTAL
Intervention: Anxiety-management training with positive self-statements
Number of subjects: 12

Group type: COMPARATOR
Intervention: Anxiety-management training with negative self-statements
Number of subjects: 12
Study: 31690303

Group type: EXPERIMENTAL
Intervention: Compression therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Negative pressure drainage (control)
Number of subjects: 60
Study: 29427263

Group type: EXPERIMENTAL
Intervention: Parks with more amenities and features, fewer incivilities and reported crimes
Number of subjects: 1003

Group type: COMPARATOR
Intervention: Parks closest to home
Number of subjects: 1003
Study: 27245155

Group type: EXPERIMENTAL
Intervention: Sublingual glyceryl trinitrate (GTN) spray
Number of subjects: 27
Study: 25313573

Group type: EXPERIMENTAL
Intervention: I40 - Basal diet supplemented with 40 mg Cu/kg DM in the form of copper sulphate
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: O40 - Basal diet supplemented with 40 mg Cu/kg DM in the form of copper proteinate
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: I10 - Basal diet supplemented with 10 mg Cu/kg DM in the form of copper sulphate
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: O10 - Basal diet supplemented with 10 mg Cu/kg DM in the form of copper proteinate
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control - Basal diet without supplementation of Cu (7 mg Cu/kg DM)
Number of subjects: 35
Study: 23055655

Group type: EXPERIMENTAL
Intervention: CO2 insufflation during colonoscopy
Number of subjects: 347
Study: 20596795

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg suspension via NG/NJ tube daily
Number of subjects: 51

Group type: COMPARATOR
Intervention: Famotidine 20 mg IV q12 h
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Both agents
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Famotidine
Number of subjects: 51
Study: 18046108

Group type: EXPERIMENTAL
Intervention: Irbesartan/Hydrochlorothiazide (HCTZ) 300/25 mg
Number of subjects: 1235

Group type: COMPARATOR
Intervention: Irbesartan 300 mg
Number of subjects: 1235

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ) 25 mg
Number of subjects: 1235
Study: 16126936

Group type: EXPERIMENTAL
Intervention: 250 mg acetazolamide
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 500 mg acetazolamide
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 12403212

Group type: EXPERIMENTAL
Intervention: Growth hormone (1,000 ng/ml)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control (without growth hormone)
Number of subjects: 47
Study: 10090337

Group type: EXPERIMENTAL
Intervention: Epinephrine (2 x 10(‐8) to 5 x 10(‐6) mol/L)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endothelin‐1 (10(‐9) mol/L)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endothelin‐1
Number of subjects: 0
Study: 7761273

Group type: EXPERIMENTAL
Intervention: MRI, 18FDG‐PET, and 99mTc‐HMPAO‐SPECT
Number of subjects: 51
Study: 1969115

Group type: EXPERIMENTAL
Intervention: Zidovudine 500 mg per day
Number of subjects: 1338

Group type: EXPERIMENTAL
Intervention: Zidovudine 1500 mg per day
Number of subjects: 1338

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1338
Study: 426989

Group type: EXPERIMENTAL
Intervention: Diazepam premedication
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pethidine premedication
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Polyethylene glycol formulation of etomidate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propylene glycol formulation of etomidate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fast injection with pethidine premedication
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unpremedicated patients
Number of subjects: 0